Headlands Technologies LLC Invests $980,000 in Celcuity, Inc. $CELC

Headlands Technologies LLC bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,368 shares of the company’s stock, valued at approximately $980,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELC. EverSource Wealth Advisors LLC raised its position in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the period. US Bancorp DE grew its stake in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the period. Parallel Advisors LLC bought a new position in Celcuity in the 1st quarter valued at about $38,000. Finally, Meeder Asset Management Inc. acquired a new stake in Celcuity during the fourth quarter worth approximately $42,000. 63.33% of the stock is owned by institutional investors.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $91.98 on Wednesday. The business has a fifty day moving average price of $94.66 and a two-hundred day moving average price of $106.96. The stock has a market capitalization of $4.50 billion, a PE ratio of -21.39 and a beta of 0.21. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a fifty-two week low of $44.42 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities analysts predict that Celcuity, Inc. will post -4.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on CELC. Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th. Needham & Company LLC lowered their price objective on Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research note on Thursday, May 28th. Finally, Wells Fargo & Company lowered their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.